NSG 533 - Exam 1 | Advanced Pharmacology (2026/2027 Edition) Wilkes University | 100 Questions - Verified Answers & Rationales
NSG533 / NSG 533 EXAM 1 (LATEST )
ADVANCED PHARMACOLOGY
Questions and Verified Answers with Rationales | 100% Correct | Grade A - Wilkes
Wilkes University NSG 533 - Advanced Pharmacology | Aligned with AACN Essentials of Master's Education
and 2026/2027 Advanced Pharmacology Competencies
Total Questions 100 Cognitive Levels 20% Recall / 50% Application / 30% Analysis
Format Multiple Choice (A-D) Question Style 75% Scenario-based / 25% Direct Knowledge
Sections 9 Pharmacology Domains Each Question Single Best Answer + Detailed Rationale
Section 1: Pharmacokinetics & Pharmacodynamics
Q1: A 68-year-old patient with hepatic cirrhosis is prescribed a drug that undergoes extensive first-pass
metabolism. The advanced practice nurse understands that, compared with a healthy adult, this patient's oral
bioavailability of the drug will likely be:
A. Decreased due to accelerated hepatic enzyme activity
B. Increased because cirrhosis reduces first-pass metabolism capacity *[CORRECT]*
C. Unchanged because first-pass metabolism occurs only in the gut wall
D. Decreased because cirrhosis increases gastric acid secretion
Correct Answer: B
Rationale: In hepatic cirrhosis, functional hepatocyte mass and enzymatic activity decline, reducing the first-pass effect
and increasing oral bioavailability (F) of drugs such as propranolol, morphine, and verapamil. Choice A is incorrect
because cirrhosis does not accelerate metabolism; choices C and D misattribute the site and mechanism of the first-pass
effect. NSG 533 emphasizes altered pharmacokinetics in hepatic impairment as a core principle of precision dosing.
Q2: A drug has a half-life of 8 hours and is administered once daily. Approximately how long will it take to
reach approximately 94% of steady-state plasma concentration?
A. 8 hours (1 half-life)
B. 16 hours (2 half-lives)
C. 32 hours (4 half-lives)
D. 40 hours (5 half-lives) *[CORRECT]*
Correct Answer: D
Rationale: Steady state is achieved after approximately 4 to 5 half-lives of repeated dosing. At 5 half-lives (5 x 8 = 40
hours), roughly 96.9% of steady state is reached; 4 half-lives achieves ~93.7%. Choice C captures the lower bound
(~94%); however, the AACN master's competency standard expects clinicians to plan dosing intervals assuming 5
half-lives for full steady state. Choice D (40 hours) reflects 5 half-lives, the conventional threshold.
Wilkes University NSG 533 - Advanced Pharmacology Page 1
,NSG 533 - Exam 1 | Advanced Pharmacology (2026/2027 Edition) Wilkes University | 100 Questions - Verified Answers & Rationales
Q3: A patient receiving a highly protein-bound drug (warfarin, 99% bound) is started on sulfamethoxazole,
which is also highly protein bound. The advanced practice nurse correctly anticipates which phenomenon?
A. Warfarin's free fraction decreases, requiring a higher maintenance dose
B. Warfarin's free fraction rises transiently, transiently increasing anticoagulant effect and bleeding risk
*[CORRECT]*
C. Warfarin metabolism is permanently induced by sulfamethoxazole
D. No clinically meaningful interaction because warfarin is renally excreted unchanged
Correct Answer: B
Rationale: Displacement from albumin transiently increases the free (active) fraction of warfarin, raising INR and
bleeding risk until redistribution and increased clearance re-equilibrate. Choice A reverses the direction; choice C
confuses displacement with enzyme induction (sulfamethoxazole actually inhibits CYP2C9); choice D is wrong because
warfarin is hepatically metabolized.
Q4: A drug with a narrow therapeutic index (TI) undergoes zero-order kinetics at high doses. Which
statement best characterizes this pharmacokinetic profile?
A. A constant fraction of the drug is eliminated per unit time
B. A constant amount of the drug is eliminated per unit time, so small dose increases can cause
disproportionate toxicity *[CORRECT]*
C. Doubling the dose doubles the rate of elimination
D. Half-life remains constant regardless of dose
Correct Answer: B
Rationale: Zero-order (saturation) kinetics means elimination processes are saturated and a fixed AMOUNT, not
fraction, is cleared per unit time (e.g., phenytoin, ethanol, high-dose aspirin). Small dose increases can produce large
plasma concentration rises and toxicity, which is why drugs with narrow TI and saturable metabolism require level
monitoring and individualized dosing per AACN advanced pharmacology competencies.
Q5: An agonist with high intrinsic activity but low affinity is best described as producing which effect at
maximal receptor occupancy?
A. Low efficacy, high potency
B. High efficacy, low potency *[CORRECT]*
C. Low efficacy, low potency
D. High efficacy, high potency
Correct Answer: B
Rationale: Efficacy (intrinsic activity) is the maximal response achievable; potency (affinity) is the concentration
producing a given effect. High intrinsic activity with low affinity yields high efficacy but low potency (a right-shifted
dose-response curve still reaching the same maximum). NSG 533 receptor theory emphasizes that potency and efficacy
are independent properties relevant to drug selection and dose titration.
Wilkes University NSG 533 - Advanced Pharmacology Page 2
,NSG 533 - Exam 1 | Advanced Pharmacology (2026/2027 Edition) Wilkes University | 100 Questions - Verified Answers & Rationales
Q6: A patient is started on phenytoin. The APRN orders a loading dose. The primary pharmacokinetic
rationale for a loading dose is to:
A. Bypass hepatic first-pass metabolism
B. Rapidly achieve therapeutic plasma concentration before steady state is reached *[CORRECT]*
C. Reduce total daily maintenance dose by half
D. Prevent development of drug tolerance
Correct Answer: B
Rationale: Loading doses (Vd x target Css) rapidly fill the volume of distribution to attain therapeutic concentrations
quickly, which is critical for drugs with long half-lives such as phenytoin, amiodarone, and digoxin. Steady state would
otherwise require 4-5 half-lives (e.g., phenytoin ~5-7 days). Choices A, C, and D mischaracterize loading dose
principles.
Q7: A patient who is a CYP2D6 poor metabolizer is prescribed codeine for postoperative pain. What is the
most likely clinical consequence?
A. Enhanced analgesia due to accumulation of active metabolite
B. Reduced analgesic efficacy because codeine requires conversion to morphine via CYP2D6 *[CORRECT]*
C. Increased respiratory depression due to morphine accumulation
D. No change in analgesic effect because codeine is directly active
Correct Answer: B
Rationale: Codeine is a prodrug requiring O-demethylation by CYP2D6 to morphine for analgesic activity. Poor
metabolizers produce little morphine and experience inadequate pain relief, while ultrarapid metabolizers risk toxicity.
This is a core pharmacogenomics example in NSG 533 precision medicine content and supports CPIC-based dosing
guidance.
Q8: Which pharmacokinetic parameter most directly determines the dosing interval of a maintenance
regimen for a renally cleared drug?
A. Volume of distribution
B. Bioavailability
C. Elimination half-life *[CORRECT]*
D. Plasma protein binding
Correct Answer: C
Rationale: Elimination half-life (t1/2 = 0.693 x Vd / CL) determines how often a drug must be administered to maintain
concentrations within the therapeutic window. With renal impairment, clearance falls, t1/2 prolongs, and dosing
intervals typically lengthen (or doses decrease) to avoid accumulation. Choices A, B, and D affect other aspects of
dosing but not the interval calculation directly.
Wilkes University NSG 533 - Advanced Pharmacology Page 3
, NSG 533 - Exam 1 | Advanced Pharmacology (2026/2027 Edition) Wilkes University | 100 Questions - Verified Answers & Rationales
Q9: A patient receives two drugs that are both substrates of the OATP1B1 hepatic uptake transporter. Which
outcome best reflects the likely drug interaction?
A. Increased hepatic uptake of both drugs, lowering plasma levels
B. Competition for hepatic uptake raises plasma concentration of the substrate with lower affinity
*[CORRECT]*
C. Induction of OATP1B1 expression increases clearance of both drugs
D. Interaction only occurs if the drugs share CYP3A4 metabolism
Correct Answer: B
Rationale: Drug transporters (e.g., OATP1B1, P-glycoprotein) mediate clinically important interactions independent of
CYP metabolism. Statins (e.g., rosuvastatin) and cyclosporine compete for OATP1B1, raising statin exposure and
myopathy risk. NSG 533 incorporates membrane transporter pharmacology as a key component of drug disposition and
interactions.
Q10: A drug has an onset of action of 30 minutes, peak effect at 2 hours, and duration of 8 hours. The most
appropriate dosing schedule for symptomatic management of an intermittent condition is:
A. Once daily at bedtime
B. Every 8 hours as needed *[CORRECT]*
C. Every 24 hours on a fixed schedule
D. Twice weekly regardless of symptoms
Correct Answer: B
Rationale: Dosing intervals generally mirror duration of action for symptomatic therapy; an 8-hour duration supports
every-8-hour PRN dosing. Once-daily or weekly dosing would not provide adequate coverage for intermittent symptoms.
The AACN advanced pharmacology competency expects APRNs to align dosing intervals with onset, peak, and duration
parameters for individualized therapy.
Q11: A competitive antagonist is administered in the presence of an agonist. Increasing the agonist dose will:
A. Have no effect because the antagonist irreversibly binds the receptor
B. Overcome the antagonist's blockade, producing a rightward shift of the dose-response curve with preserved
maximal response *[CORRECT]*
C. Reduce the maximal response due to receptor downregulation
D. Increase antagonist toxicity due to additivity
Correct Answer: B
Rationale: Competitive antagonists bind reversibly to the same receptor, so increasing agonist concentration can
surmount the blockade, producing a parallel rightward shift in the dose-response curve without reducing Emax.
Irreversible antagonists (choice A) reduce Emax. NSG 533 receptor theory contrasts competitive, noncompetitive, and
irreversible antagonism as core pharmacodynamic principles.
Wilkes University NSG 533 - Advanced Pharmacology Page 4
NSG533 / NSG 533 EXAM 1 (LATEST )
ADVANCED PHARMACOLOGY
Questions and Verified Answers with Rationales | 100% Correct | Grade A - Wilkes
Wilkes University NSG 533 - Advanced Pharmacology | Aligned with AACN Essentials of Master's Education
and 2026/2027 Advanced Pharmacology Competencies
Total Questions 100 Cognitive Levels 20% Recall / 50% Application / 30% Analysis
Format Multiple Choice (A-D) Question Style 75% Scenario-based / 25% Direct Knowledge
Sections 9 Pharmacology Domains Each Question Single Best Answer + Detailed Rationale
Section 1: Pharmacokinetics & Pharmacodynamics
Q1: A 68-year-old patient with hepatic cirrhosis is prescribed a drug that undergoes extensive first-pass
metabolism. The advanced practice nurse understands that, compared with a healthy adult, this patient's oral
bioavailability of the drug will likely be:
A. Decreased due to accelerated hepatic enzyme activity
B. Increased because cirrhosis reduces first-pass metabolism capacity *[CORRECT]*
C. Unchanged because first-pass metabolism occurs only in the gut wall
D. Decreased because cirrhosis increases gastric acid secretion
Correct Answer: B
Rationale: In hepatic cirrhosis, functional hepatocyte mass and enzymatic activity decline, reducing the first-pass effect
and increasing oral bioavailability (F) of drugs such as propranolol, morphine, and verapamil. Choice A is incorrect
because cirrhosis does not accelerate metabolism; choices C and D misattribute the site and mechanism of the first-pass
effect. NSG 533 emphasizes altered pharmacokinetics in hepatic impairment as a core principle of precision dosing.
Q2: A drug has a half-life of 8 hours and is administered once daily. Approximately how long will it take to
reach approximately 94% of steady-state plasma concentration?
A. 8 hours (1 half-life)
B. 16 hours (2 half-lives)
C. 32 hours (4 half-lives)
D. 40 hours (5 half-lives) *[CORRECT]*
Correct Answer: D
Rationale: Steady state is achieved after approximately 4 to 5 half-lives of repeated dosing. At 5 half-lives (5 x 8 = 40
hours), roughly 96.9% of steady state is reached; 4 half-lives achieves ~93.7%. Choice C captures the lower bound
(~94%); however, the AACN master's competency standard expects clinicians to plan dosing intervals assuming 5
half-lives for full steady state. Choice D (40 hours) reflects 5 half-lives, the conventional threshold.
Wilkes University NSG 533 - Advanced Pharmacology Page 1
,NSG 533 - Exam 1 | Advanced Pharmacology (2026/2027 Edition) Wilkes University | 100 Questions - Verified Answers & Rationales
Q3: A patient receiving a highly protein-bound drug (warfarin, 99% bound) is started on sulfamethoxazole,
which is also highly protein bound. The advanced practice nurse correctly anticipates which phenomenon?
A. Warfarin's free fraction decreases, requiring a higher maintenance dose
B. Warfarin's free fraction rises transiently, transiently increasing anticoagulant effect and bleeding risk
*[CORRECT]*
C. Warfarin metabolism is permanently induced by sulfamethoxazole
D. No clinically meaningful interaction because warfarin is renally excreted unchanged
Correct Answer: B
Rationale: Displacement from albumin transiently increases the free (active) fraction of warfarin, raising INR and
bleeding risk until redistribution and increased clearance re-equilibrate. Choice A reverses the direction; choice C
confuses displacement with enzyme induction (sulfamethoxazole actually inhibits CYP2C9); choice D is wrong because
warfarin is hepatically metabolized.
Q4: A drug with a narrow therapeutic index (TI) undergoes zero-order kinetics at high doses. Which
statement best characterizes this pharmacokinetic profile?
A. A constant fraction of the drug is eliminated per unit time
B. A constant amount of the drug is eliminated per unit time, so small dose increases can cause
disproportionate toxicity *[CORRECT]*
C. Doubling the dose doubles the rate of elimination
D. Half-life remains constant regardless of dose
Correct Answer: B
Rationale: Zero-order (saturation) kinetics means elimination processes are saturated and a fixed AMOUNT, not
fraction, is cleared per unit time (e.g., phenytoin, ethanol, high-dose aspirin). Small dose increases can produce large
plasma concentration rises and toxicity, which is why drugs with narrow TI and saturable metabolism require level
monitoring and individualized dosing per AACN advanced pharmacology competencies.
Q5: An agonist with high intrinsic activity but low affinity is best described as producing which effect at
maximal receptor occupancy?
A. Low efficacy, high potency
B. High efficacy, low potency *[CORRECT]*
C. Low efficacy, low potency
D. High efficacy, high potency
Correct Answer: B
Rationale: Efficacy (intrinsic activity) is the maximal response achievable; potency (affinity) is the concentration
producing a given effect. High intrinsic activity with low affinity yields high efficacy but low potency (a right-shifted
dose-response curve still reaching the same maximum). NSG 533 receptor theory emphasizes that potency and efficacy
are independent properties relevant to drug selection and dose titration.
Wilkes University NSG 533 - Advanced Pharmacology Page 2
,NSG 533 - Exam 1 | Advanced Pharmacology (2026/2027 Edition) Wilkes University | 100 Questions - Verified Answers & Rationales
Q6: A patient is started on phenytoin. The APRN orders a loading dose. The primary pharmacokinetic
rationale for a loading dose is to:
A. Bypass hepatic first-pass metabolism
B. Rapidly achieve therapeutic plasma concentration before steady state is reached *[CORRECT]*
C. Reduce total daily maintenance dose by half
D. Prevent development of drug tolerance
Correct Answer: B
Rationale: Loading doses (Vd x target Css) rapidly fill the volume of distribution to attain therapeutic concentrations
quickly, which is critical for drugs with long half-lives such as phenytoin, amiodarone, and digoxin. Steady state would
otherwise require 4-5 half-lives (e.g., phenytoin ~5-7 days). Choices A, C, and D mischaracterize loading dose
principles.
Q7: A patient who is a CYP2D6 poor metabolizer is prescribed codeine for postoperative pain. What is the
most likely clinical consequence?
A. Enhanced analgesia due to accumulation of active metabolite
B. Reduced analgesic efficacy because codeine requires conversion to morphine via CYP2D6 *[CORRECT]*
C. Increased respiratory depression due to morphine accumulation
D. No change in analgesic effect because codeine is directly active
Correct Answer: B
Rationale: Codeine is a prodrug requiring O-demethylation by CYP2D6 to morphine for analgesic activity. Poor
metabolizers produce little morphine and experience inadequate pain relief, while ultrarapid metabolizers risk toxicity.
This is a core pharmacogenomics example in NSG 533 precision medicine content and supports CPIC-based dosing
guidance.
Q8: Which pharmacokinetic parameter most directly determines the dosing interval of a maintenance
regimen for a renally cleared drug?
A. Volume of distribution
B. Bioavailability
C. Elimination half-life *[CORRECT]*
D. Plasma protein binding
Correct Answer: C
Rationale: Elimination half-life (t1/2 = 0.693 x Vd / CL) determines how often a drug must be administered to maintain
concentrations within the therapeutic window. With renal impairment, clearance falls, t1/2 prolongs, and dosing
intervals typically lengthen (or doses decrease) to avoid accumulation. Choices A, B, and D affect other aspects of
dosing but not the interval calculation directly.
Wilkes University NSG 533 - Advanced Pharmacology Page 3
, NSG 533 - Exam 1 | Advanced Pharmacology (2026/2027 Edition) Wilkes University | 100 Questions - Verified Answers & Rationales
Q9: A patient receives two drugs that are both substrates of the OATP1B1 hepatic uptake transporter. Which
outcome best reflects the likely drug interaction?
A. Increased hepatic uptake of both drugs, lowering plasma levels
B. Competition for hepatic uptake raises plasma concentration of the substrate with lower affinity
*[CORRECT]*
C. Induction of OATP1B1 expression increases clearance of both drugs
D. Interaction only occurs if the drugs share CYP3A4 metabolism
Correct Answer: B
Rationale: Drug transporters (e.g., OATP1B1, P-glycoprotein) mediate clinically important interactions independent of
CYP metabolism. Statins (e.g., rosuvastatin) and cyclosporine compete for OATP1B1, raising statin exposure and
myopathy risk. NSG 533 incorporates membrane transporter pharmacology as a key component of drug disposition and
interactions.
Q10: A drug has an onset of action of 30 minutes, peak effect at 2 hours, and duration of 8 hours. The most
appropriate dosing schedule for symptomatic management of an intermittent condition is:
A. Once daily at bedtime
B. Every 8 hours as needed *[CORRECT]*
C. Every 24 hours on a fixed schedule
D. Twice weekly regardless of symptoms
Correct Answer: B
Rationale: Dosing intervals generally mirror duration of action for symptomatic therapy; an 8-hour duration supports
every-8-hour PRN dosing. Once-daily or weekly dosing would not provide adequate coverage for intermittent symptoms.
The AACN advanced pharmacology competency expects APRNs to align dosing intervals with onset, peak, and duration
parameters for individualized therapy.
Q11: A competitive antagonist is administered in the presence of an agonist. Increasing the agonist dose will:
A. Have no effect because the antagonist irreversibly binds the receptor
B. Overcome the antagonist's blockade, producing a rightward shift of the dose-response curve with preserved
maximal response *[CORRECT]*
C. Reduce the maximal response due to receptor downregulation
D. Increase antagonist toxicity due to additivity
Correct Answer: B
Rationale: Competitive antagonists bind reversibly to the same receptor, so increasing agonist concentration can
surmount the blockade, producing a parallel rightward shift in the dose-response curve without reducing Emax.
Irreversible antagonists (choice A) reduce Emax. NSG 533 receptor theory contrasts competitive, noncompetitive, and
irreversible antagonism as core pharmacodynamic principles.
Wilkes University NSG 533 - Advanced Pharmacology Page 4
